In 2015, published trials highlighted the remarkable efficacy of docetaxel combined with androgen-deprivation therapy in patients with newly diagnosed metastatic prostate cancer. Also in 2015, a large study revealing potential molecular targets for metastatic castration-resistant prostate cancer therapies was published, along with a study showing activity of PARP inhibition in patients harbouring mutations in genes governing DNA repair.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Petrylak, D. P. Docetaxel-based chemotherapy trials in androgen-independent prostate cancer: first demonstration of a survival benefit. Curr. Oncol. Rep. 7, 205–206 (2005).
Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737–746 (2015).
Yamaoka, M. et al. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J. Steroid. Biochem. Mol. Biol. 129, 115–128 (2012).
Saad, F. et al. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, Phase 3, randomised, placebo-controlled trial. Lancet Oncol. 16, 338–348 (2015).
Fizazi, K. et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J. Clin. Oncol. 33, 723–731 (2015).
Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).
Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424–433 (2014).
Gartrell, B. A. & Saad, F. Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy. Ther. Adv. Urol. 7, 194–202 (2015).
Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215–1228 (2015).
Kaufman, B. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33, 244–250 (2015).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Related links
Web links
Rights and permissions
About this article
Cite this article
Graff, J., Beer, T. The new and the old that is new again. Nat Rev Clin Oncol 13, 73–74 (2016). https://doi.org/10.1038/nrclinonc.2015.226
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.226